Market: NASD |
Currency: USD
Address: 321 Harrison Avenue
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
📈 HilleVax, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$2.00
-
Upside/Downside from Analyst Target:
-3.15%
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-07
-
EPS Estimate:
-0.15
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for HilleVax, Inc.
| Date | Reported EPS |
|---|
| 2025-11-06 (estimated upcoming) | - |
| 2025-08-06 | -0.11 |
| 2025-05-08 | -0.12 |
| 2025-03-28 | -0.26 |
| 2024-11-07 | -0.52 |
| 2024-08-09 | -0.66 |
| 2024-05-09 | -0.97 |
| 2024-03-20 | -0.78 |
| 2023-11-09 | -0.81 |
| 2023-08-14 | -0.74 |
| 2023-05-12 | -0.71 |
| 2023-03-17 | -0.56 |
| 2022-11-10 | -0.45 |
| 2022-08-10 | -2.03 |
| 2022-06-08 | -10.06 |
📰 Related News & Research
No related articles found for "hillevax inc".
